Literature DB >> 2295115

Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells.

E Aghaï1, Z A Tökés.   

Abstract

In vitro accumulation of doxorubicin in intracellular compartments of normal bone marrow cells was studied with the use of fluorescent microscopy. Both the cytoplasmic and nuclear compartments had distinguishable drug accessibility in the diverse hemopoietic series and in different stages of maturation of each lineage. Nuclei appeared to be more sheltered in the myelogranulocytic series than in the nucleated erythroid cells. Nuclei of activated phagocytic cells of the myelogranulocytic series and macrophages appeared to be the least accessible to doxorubicin uptake. These observations establish that phenotypic variations dictate the patterns of anthracyclines' subcellular compartmentalization. They also suggest that the molecular mechanism contributing to the intracellular trafficking of doxorubicin deserves more substantial investigation that may contribute to our understanding of drug resistance and sensitivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295115     DOI: 10.1007/bf00684889

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells.

Authors:  H Hamada; T Tsuruo
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

Review 2.  Inhibitors of DNA topoisomerases.

Authors:  K Drlica; R J Franco
Journal:  Biochemistry       Date:  1988-04-05       Impact factor: 3.162

3.  Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells.

Authors:  M C Willingham; N D Richert; M M Cornwell; T Tsuruo; H Hamada; M M Gottesman; I H Pastan
Journal:  J Histochem Cytochem       Date:  1987-12       Impact factor: 2.479

Review 4.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

5.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

6.  Photoaffinity labeling of the Sarcoma 180 cell surface by daunomycin.

Authors:  G Yee; M Carey; T R Tritton
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

Review 7.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

8.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.

Authors:  G Batist; A Tulpule; B K Sinha; A G Katki; C E Myers; K H Cowan
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

9.  Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils.

Authors:  P Vaudaux; B Kiefer; M Forni; I Joris; G Majno; F A Waldvogel
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

10.  Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity.

Authors:  E S Kleinerman; L A Zwelling; R Schwartz; A V Muchmore
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

View more
  2 in total

1.  Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.

Authors:  Elon C Roti Roti; Scott K Leisman; David H Abbott; Sana M Salih
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

2.  Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining.

Authors:  H P Henneberry; G W Aherne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.